The study, conducted by Imperial College Health Partners, also showed a significant quality of life benefits for men treated with the UroLift System when compared to those treated with TURP. Unlike TURP, the UroLift System does not involve any cutting or removal of tissue and typically does not require general anesthesia, post-operative catheterization, or overnight hospitalization. On average, the hospitalization for men undergoing TURP is 2.7 days1. The UroLift System is the only minimally invasive treatment option for BPH that has been shown to provide rapid and durable symptomatic and urinary flow rate improvement without inducing sustained sexual dysfunction.2
“The data analysis from this study sheds new light on the potential cost savings and improved patient outcomes associated with the prostatic urethral lift treatment”
More than two million men have been diagnosed with BPH in the United Kingdom3, yet fewer than two percent elect to have surgery.4 Approximately 15,000 TURP procedures are performed across England and Wales each year for the treatment of BPH.5
“The data analysis from this study sheds new light on the potential cost savings and improved patient outcomes associated with the prostatic urethral lift treatment,” said co-author Mr. Oliver Kayes of Leeds Teaching Hospitals NHS Trust. “Post-surgery complications including urinary tract infections and blood transfusions are expensive complications of TURP and burdensome to men. The UroLift System offers men a new minimally invasive option that reduces the occurrence of these unpleasant side effects.”
“The UroLift System has a demonstrated record of success among patients, their physicians, and payers in the United States as demonstrated by the recent addition of the prostatic urethral lift treatment into the American Urological Association’s new guidelines on the effective management of BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see this independent analysis highlighting the economic benefits to the NHS and improved quality of life British men may experience with the UroLift System treatment.”
The analysis was recognized as the Best General Poster Research Presentation at the 2018 International Society For Pharmacoeconomics and Outcomes Research annual meeting.
References:
1 https://imperialcollegehealthpartners.com/wp-content/uploads/2018/05/Neotract_ISPOR_v7-2.pdf
2 No instances of new sustained erectile or ejaculatory dysfunction McVary; Roehrborn, J Urology 2013 LIFT Study.
3 Trueman, BJU Intl 1999; 83: 410-415
4 van Exel, NJA et al., Eur Urol 2006; 49: 92-102
5 https://www.nice.org.uk/guidance/mtg23/documents/the-turis-system-for-transurethral-resection-of-the-prostate-final-scope2
Read More:
5 Year Results of The Prostatic Urethral LIFT Pivotal Study
NeoTract Announces Data from Large Real-World Study of UroLift®System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate
FDA Grants Clearance of Expanded Indications for UroLift® System